ACE2 and ovarian serous cystadenocarcinoma: Moreover, we investigated the clinical relevance of ACE2 expression through GEPIA and found that the expression of ACE2 was associated with better OS and DFS in KIRC, LIHC (Fig. 4b) and ovarian serous cystadenocarcinoma (OV) patients.